Hepatitis in alcohol and drug misusers: Practical issues

Addiction Biology

Volumn 2, Issue 4, 1997, Pages 411-420

  Cramp, Matthew E ^a   Williams, Roger ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY;

ALCOHOL ABUSE; BEHAVIOR; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; NONHUMAN; PRIORITY JOURNAL; REHABILITATION CENTER; REVIEW; UNITED KINGDOM; VIRUS HEPATITIS;

EID: 0030699048     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556219772462     Document Type: Review

References (62)

1. Laboratory reports of hepatitis A virus infections to PHLS CDSC England and Wales, 1983-1994 by specimen year. Data to 31/5/95. London: Public Health Laboratory Service, 1995.
2. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989;110:838-9.
3. O'Grady JG. Risk factors for severe hepatitis A virus infection. Hepatocite 1995;12:4-5.
4. Forbes A, Williams R. Increasing age - an important adverse prognostic factor in hepatitis A virus infection. J R Coll Physicians Lond 1988;22:237-9.
5. Ambrosch F, Wiedermann G, Andre FE, et al. Clinical and immunological investigation of a new combined hepatitis A and B vaccine. J Med Virol 1994;44:452-6.
6. Short R, Long G, editors. Incidence and prevalence rates in the UK. Hepatitis B in the UK; 1986. London: Royal Society of Medicine, 1986.
7. King R, Johnson PJ, White YS, Smith HM, Williams R. Frequency of asymptomatic hepatitis types B and C in an inner city community and relation to possible risk factors. Q J Med 1991;80:641-9.
8. Rhodes T, Hunter GM, Stimson GV, et al. Prevalence of markers for hepatitis B virus and HIV-1 among drug injectors in London: injecting careers, positivity and risk behaviour. Addiction 1996;91: 1457-67.
9. Crofts N, Stewart T, Hearne P, Ping XY, Breshkin AM, Locarnini SA. Spread of bloodborne viruses among Australian prison entrants. Br Med J 1995; 310:285-8.
10. Johnson AM, Wadsworth J, Welling K, Field J. Sexual attitudes and lifestyles. Oxford: Blackwell Scientific Publications, 1994.
11. Hall AJ. Hepatitis B vaccination: protection for how long and against what? Br Med J 1993;307:276-7.
12. Zuckerman JN, Sabin C, Craig F, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. Br Med J 1997;314: 329-33.
13. Laboratory reports of acute HBV infections to PHLS CDSC England and Wales. Data to 31/12/94. London: Public Health Laboratory Service, 1995.
14. Wong V, Wreghitt TG, Alexander GJ. Prospective study of hepatitis B vaccination in patients with chronic hepatitis C. Br Med J 1996;312:1336-7.
15. Farrell M, Battersby M, Strang J. Screening for hepatitis B and vaccination of injecting drug users in NHS drug treatment services. Br J Addict 1990; 85:1657-9.
16. Mangtani P, Kovats S, Hall A. Hepatitis B vaccination policy in drug treatment services (letter). Br Med J 1995;311:1500.
17. Wong DK, Cheung AM, K OR, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
18. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
19. Hoofnagle JH. Type D (delta) hepatitis [clinical conference] [published erratum appears in JAMA 1989 Jun 23-30;261:3552]. JAMA 1989;261: 1321-5.
20. Rosina F, Saracco G, Lattore V. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. In: Rizetto M, Gerin JL, Purcell RH, editors. Hepatitis delta virus and its infection. New York: Alan R Liss, 1987:299-303.
21. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
22. van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;344:1475-9.
23. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
24. Brechot C. Hepatitis C virus genetic variability: clinical implication. Am J Gastroenterol 1994;89: S41-S47.
25. Pol S, Squadritto G, Thiers V, Berthelot P, Brechot C. Is the sexual transmission of HCV real? Hepatology 1995;22:348A.
26. Bresters D, Mauser-Bunschoten EP, Reesink HW, et al. Sexual transmission of hepatitis C virus. Lancet 1995;342:210-11.
27. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin (see comments). Lancet 1995;345: 1209-11.
28. Thomas DL, Zenilman, JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-75.
29. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus liver infection. N Engl J Med 1996;344:1691-6.
30. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group (see comments). N Engl J Med 1994;330:744-50.
31. Dow BC, Coote I, Munro H, et al. Confirmation of hepatitis C virus antibody in blood donors. J Med Virol 1993;41:215-20.
32. Hepatitis C and drug addiction in France, epidemiology and therapeutic consequences. Mainliners Hepatitis C Conference. London: Regents Park College, 1996.
33. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74:212-20.
34. Waller TAN, Holmes R. The prevalence and management of hepatitis C in injecting drug users attending drug services in the United Kingdom. London: Tavistock, 1995.
35. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15: 70-81.
36. Obaid Shakil A, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995;123:330-7.
37. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
38. Esteban JI, Lopez Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-9.
39. Poynard T, Bedossa P, Opolon P, for the OBSVIRC M, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
40. Tong MJ, el Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
41. Tong MJ, el Farra NS. Clinical sequelae of hepatitis C acquired from injection drug use. West J Med 1996;164:399-404.
42. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. Intravenous drug use. Hepatology 1993;18:1338-43.
43. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 1994;87:555-61.
44. Seef LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906.
45. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995;15:101-9.
46. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatalogy 1994; 20:1115-20.
47. Yamauchi M, Nakahara M, Maezawa Y, et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993;88:39-43.
48. Mendenhall CL, Moritz T, Rouster S. Epidemiology of hepatitis C among veterans with alcoholic liver disease. Am J Gastroenterol 1993;88:1022-6.
49. Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996;334: 1536-7.
50. Aikawa T, Sugai Y, Okamoto H. Hepatitis G infection in drug abusers with chronic hepatitis C. N Engl J Med 1996;334:195-6.
51. Alter MJ, Gallagher M, Morris T, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997;336: 741-6.
52. Miyakawa Y, Mayumi M. Hepatitis G virus - a true hepatitis virus or an accidental tourist? N Engl J Med 1997;336:795-6.
53. Terrault N, Wright T. Interferon and hepatitis C virus infection. N Engl J Med 1995;332:1509-11.
54. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
55. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82-91.
56. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15: 1013-6.
57. Booth JC, Brown JL, Thomas HC. The management of chronic hepatitis C virus infection. Gut 1995;37:449-54.
58. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
59. Boker KH, Ringe B, Kruger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57: 1706-8.
60. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
61. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
62. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 Suppl 2;8-12.